Recombinant adenovirus modified PBMC-derived dendritic cells are resistant to HIV-1 infection
- Author:
Cheng-Lai XIA
1
Author Information
1. Department of Pharmacy
- Publication Type:Journal Article
- Keywords:
Dendritic cell;
Gene therapy;
Human immunodeficiency virus-1;
Peripheral blood monouclear cells;
Recombinant adenovirus
- From:
Chinese Pharmaceutical Journal
2012;47(12):960-964
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE: To identify the characteristics of recombinant adenovirus modified PBMC-derived dendritic cells to resist the HIV-1 infection. METHODS: The recombinant adenovirus vector was integrated with CCR5A32, CCR5siRNA, HIV-1 poli and HIV-1 inti genes by using AdEasy system. The human PBMC from healthy donor blood was isolated in order to get dendritic cells. The expression of CCR5Δ32, CCR5, CXCR4 and HIV-1 P24 in PBMC or modified cells was measured by Westernblot. RESULTS: After the cells have been modified by Ad-R5Δ32siHIV, the expression of CCR5Δ32 was increased while the expression of CCR5 and CXCR4 were decreased. The level of p24 was lower in modified cells than that of unmodified cells. The modified cells show resistance to HIV-1 infection. CONCLUSION: The recombinant adenovirus-modified cells show good resistance to HIV-1 infection. Modification of HSC-derived immunity cells, such as DCs, may be a potent strategy to resist HIV-1 infection.
